A personalized network framework reveals predictive axis of anti-TNF response across diseases
Shiran Gerassy-VainbergiD, Elina Starosvetsky, Renaud Gaujoux, Alexandra Blatt, Naama Maimon, Yuri GorelikiD, Sigal Pressman, Ayelet Alpert, Haggai Bar‐YosephiD, Tania Dubovik, Benny Perets, Adir Katz, Neta MilmaniD, Meital Segev, Yehuda Chowers, Shai S. Shen-OrriD
Abstract
Personalized treatment of complex diseases has been mostly predicated on biomarker identification of one drug-disease combination at a time. Here, we used a novel computational approach termed Disruption Networks to generate a new data type, contextualized by cell-centered individual-level networks, that captures biology otherwise overlooked when performing standard statistics. The new data-type extends beyond the feature level space, to the relations space, by quantifying individual-level breaking or rewiring of cross-feature relations. Applying disruption network to dissect high-dimensional blood data, we discover and validate that the RAC1-PAK1 axis is predictive of anti-TNF response in inflammatory bowel disease. Intermediate monocytes, which correlate with the inflammatory state, play a key role in the RAC1-PAK1 responses, supporting their modulation as a therapeutic target. This axis also predicts response in rheumatoid arthritis, validated in three public cohorts. Our findings support blood-based drug response diagnostics across immune-mediated diseases, implicating common mechanisms of non-response.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 12
- FWCI
- 1.99
- Field percentile
- top 13%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cytokine interaction networks, not individual cytokines, drive anti-TNF response in Crohn's disease
Marton L. Olbei, John P. Thomas, … Tamas Douglas Korcsmaros·bioRxiv·Aug 11, 2026
- The Clinical Response of Upadacitinib and Risankizumab is Associated with Reduced Inflammatory Bowel Disease Anti-TNFα Inadequate Response Mechanisms
J. Wang, M. Macoritto, … X. Cao·bioRxiv·May 16, 2022
- Hyperactive chemotaxis contributes to anti-TNFα treatment resistance in inflammatory bowel disease
Tung On Yau, Jayakumar Narayanan Vadakekolathu, … Sergio Rutella·Journal of Gastroenterology and HepatologyPeer-reviewed·Dec 20, 2021
- A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
T. Thomas, C. Rich-Griffin, … C. Buckley·Nature ImmunologyPeer-reviewed·Oct 22, 2024
- Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in rheumatoid arthritis patients
Lucía Santiago-Lamelas, Patricia Castro-Santos, … Roberto Díaz‐Peña·Annals of the Rheumatic DiseasesPeer-reviewed·Sep 3, 2025
- scDrugPrio: A framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases
S. Schaefer, M. Smelik, … M. Benson·bioRxiv·Nov 8, 2023